Literature DB >> 28088580

Anticoagulation in chronic liver disease.

Ameet Dhar1, Benjamin H Mullish1, Mark R Thursz2.   

Abstract

In this Grand Round presentation, the case of a man with decompensated liver disease is described. He subsequently developed a fatal pulmonary embolism, which may not have occurred if he had been prescribed prophylactic anticoagulation to prevent venous thromboembolic disease. The burden of thrombotic disease in those with chronic liver disease is discussed, before a more detailed analysis of the current evidence, safety data, and clinical dilemmas regarding the use of anticoagulation in patients with chronic liver disease. Finally, the future directions within this field are explored.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anticoagulation; Cirrhosis; Direct oral anticoagulants; Heparin; Liver diseases; Teaching rounds; Thromboembolism; Thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28088580     DOI: 10.1016/j.jhep.2017.01.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

Review 1.  The multifaceted role of fibrinogen in tissue injury and inflammation.

Authors:  James P Luyendyk; Jonathan G Schoenecker; Matthew J Flick
Journal:  Blood       Date:  2018-12-06       Impact factor: 22.113

Review 2.  Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants.

Authors:  Jean Terrier; Youssef Daali; Pierre Fontana; Chantal Csajka; Jean-Luc Reny
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

Review 3.  Role of the blood coagulation cascade in hepatic fibrosis.

Authors:  Asmita Pant; Anna K Kopec; James P Luyendyk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-05-03       Impact factor: 4.052

4.  Bleeding Risk of Therapeutic Unfractionated Heparin and Low Molecular Weight Heparin in Patients with Cirrhosis.

Authors:  Katherine L Summers; Kyle A Davis; Sarah A Nisly
Journal:  Clin Drug Investig       Date:  2020-02       Impact factor: 2.859

5.  Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review.

Authors:  Zhi-Chun Huang; Chang-Qing Li; Xiao-Yu Liu; Zhong-Chao Cao; Hai-Yu Jia; Ying Dong; Tian-Long Liu; Jian-Jun Sun
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-03       Impact factor: 3.727

6.  Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference.

Authors:  N M Intagliata; C K Argo; J G Stine; T Lisman; S H Caldwell; F Violi
Journal:  Thromb Haemost       Date:  2018-07-30       Impact factor: 5.249

7.  Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.

Authors:  Hsin-Fu Lee; Yi-Hsin Chan; Shang-Hung Chang; Hui-Tzu Tu; Shao-Wei Chen; Yung-Hsin Yeh; Lung-Sheng Wu; Chang-Fu Kuo; Chi-Tai Kuo; Lai-Chu See
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

8.  Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study.

Authors:  Peter Jepsen; Elliot B Tapper; Thomas Deleuran; Konstantin Kazankov; Gro Askgaard; Henrik Toft Sørensen; Hendrik Vilstrup; Joe West
Journal:  Hepatology       Date:  2021-09-09       Impact factor: 17.425

Review 9.  Extracellular Vesicles as Carriers of Non-coding RNAs in Liver Diseases.

Authors:  Junfa Yang; Changyao Li; Lei Zhang; Xiao Wang
Journal:  Front Pharmacol       Date:  2018-04-24       Impact factor: 5.810

Review 10.  Current and future pharmacological therapies for managing cirrhosis and its complications.

Authors:  David Kockerling; Rooshi Nathwani; Roberta Forlano; Pinelopi Manousou; Benjamin H Mullish; Ameet Dhar
Journal:  World J Gastroenterol       Date:  2019-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.